Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology

Anemia is a frequent complication of cancer and of its treatments. It produces many unwanted symptoms and significantly impairs metabolic and physiologic functions, as well as patients' activity, well-being and quality of life. Life expectancy can also be adversely affected. This book, now in its second edition, offers a comprehensive presentation of current knowledge on anemia in cancer and its treatment with Recombinant Human Erythropoietin (rhEPO). In expanded, updated and newly added chapters, including a broader spectrum of topics, outstanding international experts describe the scientific and clinical aspects of anemia in various fields of oncology and give diagnostic and therapeutic recommendations on when and how to use rhEPO. Future prospects in research and development are also discussed. The book, widely considered a standard work, will continue to serve as an essential source of information for radiotherapists, medical oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion and laboratory medicine, and pharmacologists.